<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>04297naa a22005897i 4500</leader>
  <controlfield tag="001">UMUN-OA-20261005-MLS-024</controlfield>
  <controlfield tag="003">local</controlfield>
  <controlfield tag="005">20261005174903.0</controlfield>
  <controlfield tag="006">m     o  d        </controlfield>
  <controlfield tag="007">cr||||||||||||</controlfield>
  <controlfield tag="008">261005s2017    xx      o    u000 0 eng d</controlfield>
  <datafield tag="024" ind1="7" ind2=" ">
    <subfield code="a">10.1007/s12325-017-0612-x</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
    <subfield code="a">(local)EuropePMC:PMC5656728</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">local</subfield>
    <subfield code="b">eng</subfield>
    <subfield code="c">local</subfield>
  </datafield>
  <datafield tag="041" ind1="0" ind2=" ">
    <subfield code="a">eng</subfield>
  </datafield>
  <datafield tag="100" ind1="0" ind2=" ">
    <subfield code="a">Gilles Salles</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
    <subfield code="a">Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. /</subfield>
    <subfield code="c">Gilles Salles; Martin Barrett; Robin Fo&#xE0; [and others].</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2="1">
    <subfield code="a">[Place of publication not identified] :</subfield>
    <subfield code="b">[publisher not identified],</subfield>
    <subfield code="c">2017.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">1 online resource (1 article).</subfield>
  </datafield>
  <datafield tag="336" ind1=" " ind2=" ">
    <subfield code="a">text</subfield>
    <subfield code="b">txt</subfield>
    <subfield code="2">rdacontent</subfield>
  </datafield>
  <datafield tag="337" ind1=" " ind2=" ">
    <subfield code="a">computer</subfield>
    <subfield code="b">c</subfield>
    <subfield code="2">rdamedia</subfield>
  </datafield>
  <datafield tag="338" ind1=" " ind2=" ">
    <subfield code="a">online resource</subfield>
    <subfield code="b">cr</subfield>
    <subfield code="2">rdacarrier</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Publication type: Review article.</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Linked open-access copy: published version.</subfield>
  </datafield>
  <datafield tag="506" ind1="0" ind2=" ">
    <subfield code="a">Open access; no subscription required for the linked open-access version.</subfield>
    <subfield code="f">Unrestricted online access</subfield>
    <subfield code="2">star</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
    <subfield code="a">Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue. Funding F. Hoffmann-La Roche Ltd., Basel, Switzerland.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution-NonCommercial. See the linked licence for the applicable terms.</subfield>
    <subfield code="u">https://creativecommons.org/licenses/by-nc/4.0/</subfield>
  </datafield>
  <datafield tag="546" ind1=" " ind2=" ">
    <subfield code="a">In English.</subfield>
  </datafield>
  <datafield tag="588" ind1="0" ind2=" ">
    <subfield code="a">Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.</subfield>
  </datafield>
  <datafield tag="590" ind1=" " ind2=" ">
    <subfield code="a">Course allocation: B. Sc. Medical Laboratory Science.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Safety</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Monoclonal antibody</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">CD20</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Treatment outcome</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Follicular Lymphoma</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="4">
    <subfield code="a">Rituximab</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">B. Sc. Medical Laboratory Science</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">UMUN open access collection</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">hematology</subfield>
  </datafield>
  <datafield tag="655" ind1=" " ind2="4">
    <subfield code="a">Review articles.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Martin Barrett</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Robin Fo&#xE0;</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Joerg Maurer</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Susan O'Brien</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Nancy Valente</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">Michael Wenger</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="700" ind1="0" ind2=" ">
    <subfield code="a">David G Maloney</subfield>
    <subfield code="e">author.</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
    <subfield code="t">Advances in therapy</subfield>
    <subfield code="g">Vol. 34, no. 10, (2017), pages/article 2232-2273</subfield>
    <subfield code="x">0741-238X</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
    <subfield code="u">https://europepmc.org/articles/PMC5656728</subfield>
    <subfield code="y">Read open-access publication</subfield>
    <subfield code="z">Open access.</subfield>
    <subfield code="7">0</subfield>
  </datafield>
  <datafield tag="884" ind1=" " ind2=" ">
    <subfield code="a">Course selection and automated MARC21 enrichment from Europe PMC metadata.</subfield>
    <subfield code="g">20261005</subfield>
    <subfield code="k">https://europepmc.org/articles/PMC5656728</subfield>
    <subfield code="q">local</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="n">0</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">1166</subfield>
    <subfield code="d">1166</subfield>
  </datafield>
</record>
